Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

NCT03884998 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Indolent Non-Hodgkin Lymphoma
Lymphoplasmacytic Lymphoma
Marginal Zone Lymphoma
Richter Syndrome

Interventions

DRUG: Copanlisib
BIOLOGICAL: Nivolumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]